Skip to main content

Myozyme FDA Approval History

FDA Approved: Yes (First approved April 28, 2006)
Brand name: Myozyme
Generic name: alglucosidase alfa
Company: Genzyme Corp.
Treatment for: Pompe disease

Myozyme is a recombinant formulation of the human enzyme acid alpha-glucosidase (GAA) indicated for use in patients with Pompe disease (GAA deficiency), a debilitating and often fatal muscle disorder.

Development timeline for Myozyme

Apr 28, 2006Approval Myozyme Approved - Genzyme Corp. - Treatment for Pompe Disease
Jan 17, 2006Genzyme Provides Update on U.S. Marketing Application for Myozyme
Jul 29, 2005Genzyme Submits BLA for Myozyme for Treatment of Pompe Disease

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.